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In 2000–2001, 840 clinical isolates of Haemophilus influenzae were collected from labora-
tories in France, Germany, Italy and Spain (210 isolates/country). b-Lactamase produc-
tion among the isolates varied considerably by country, ranging from 8.1% in Germany to
34.8% in France. H. influenzae from patients 4 years old showed the highest prevalence
of b-lactamase production (23.2%), compared with isolates from patients aged 5–17 years
(17.8%) and 18 years (16.5%). All isolates were susceptible to amoxicillin–clavulanate,
ciprofloxacin and levofloxacin; 99.6% and 98.9% of isolates were susceptible to azithro-
mycin and cefuroxime, respectively. Among the macrolides tested, azithromycin (MIC90,
2 mg/L) was eight-fold more potent than clarithromycin (MIC90, 16 mg/L) and roxi-
thromycin (MIC90, 16 mg/L). Despite variations in b-lactamase production between
different countries, >99% of all isolates were susceptible to amoxicillin–clavulanate,
ciprofloxacin, levofloxacin, and azithromycin.
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Haemophilus influenzae is a common causative
agent of otitis media in children and acute exacer-
bations of chronic bronchitis in the elderly, and is
also isolated from patients with sinusitis and other
community-acquired respiratory infections [1,2].
b-Lactamase-mediated resistance in H. influenzae,
encoded by TEM-1 and ROB-1, has been shown to
account for most resistance to ampicillin, amox-
icillin, and some oral cephalosporins [3–5]. As a
result, aminopenicillins, in the absence of a b-
lactamase inhibitor, are not used as first-line thera-
pies for community-acquired respiratory tract
infections in some countries. The prevalence of
b-lactamase production among H. influenzae
strains has been shown to vary among European
countries [6]. Differences in empirical prescription
guidelines and the availability of antimicrobial
agents may contribute to differences in resistance
in certain countries. This report summarizes data
from a surveillance study of H. influenzae isolates
collected from clinical laboratories in four Eur-
opean countries in 2000–2001.
M A T E R I A L S A N D M E T H O D S
During 2000–2001, 840 isolates of H. influenzae were
prospectively collected from patient specimens at
20 hospital laboratories in France, Germany, Italy
and Spain (from five laboratories in each country).
The location of the participating laboratories was
representative of the various geographic regions in
each of the countries. Patient demographic infor-
mation, including age, specimen source (blood,
cerebrospinal fluid, respiratory, other) and patient
location (inpatient, outpatient) was collected for
each isolate. In total, 220 (26.2%) isolates were
collected from patients 4 years old, 101 (12.0%)
from patients 5–17 years old, 460 (54.7%) from
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Table 1 Susceptibility of H. influenzae to antimicrobial agents according to b-lactamase status
Francea Germanyb Italyc Spaind
MIC90
(mg/L) %Se %Ie %Re
MIC90
(mg/L) %S %I %R
MIC90
(mg/L) %S %I %R
MIC90
(mg/L) %S %I %R
Ampicillin
All >16 64.8 0.5 34.8 1 91.9 0 8.1 1 90.5 1.0 8.6 > 16 75.7 0.5 23.8
b-Lactamase-
negative
0.5 99.3 0.7 0 0.5 100 0 0 0.5 99.0 1.0 0 0.5 99.4 0.6 0
b-Lactamase-
positive
>16 0 0 100 > 16 0 0 100 > 16 0 0 100 > 16 0 0 100
Amoxicillin–
clavulanate
All 2 100 –f 0 1 100 – 0 1 100 – 0 2 100 – 0
b-Lactamase-
negative
1 100 – 0 0.5 100 – 0 0.5 100 – 0 1 100 – 0
b-Lactamase-
positive
2 100 – 0 2 100 – 0 2 100 – 0 4 100 – 0
Cefaclor
All 32 72.9 13.3 13.8 16 87.1 10.5 2.4 16 85.2 10.5 4.3 32 71.9 11.4 16.7
b-Lactamase-
negative
8 91.2 7.3 1.5 8 90.7 7.8 1.6 16 88.5 8.9 2.6 16 83.1 8.1 8.8
b-Lactamase-
positive
64 38.4 24.7 37.0 32 47.1 41.2 11.8 32 50.0 27.8 22.2 > 64 36.0 22.0 42.0
Cefuroxime
All 2 100 0 0 2 99.5 0.5 0 2 99.5 0.5 0 4 96.7 3.3 0
b-Lactamase-
negative
2 100 0 0 2 99.5 0.5 0 2 99.5 0.5 0 4 95.6 4.4 0
b-Lactamase-
positive
4 100 0 0 4 100 0 0 1 100 0 0 2 100 0 0
Azithromycin
All 2 99.5g – – 2 100 – – 2 100 – – 2 99.0h – –
b-Lactamase-
negative
2 99.3 – – 2 100 – – 2 100 – – 2 98.8 – –
b-Lactamase-
positive
2 100 – – 2 100 – – 2 100 – – 2 100 – –
Clarithromycin
All 16 81.9 17.6 0.5 16 82.9 16.7 0.5 16 76.7 22.4 1.0 16 77.6 21.4 1.0
b-Lactamase-
negative
16 86.1 13.1 0.7 16 83.4 16.1 0.5 16 77.1 22.4 0.5 16 80 19.4 0.6
b-Lactamase-
positive
16 74.0 26.0 0 16 76.5 23.5 0 16 72.2 22.2 5.6 16 70 28.0 2.0
Roxithromycin
All 16 – – – 16 – – – 16 – – – 16 – – –
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b-Lactamase-
negative
16 – – – 16 – – – 16 – – – 16 – – –
b-Lactamase-
positive
16 – – – 16 – – – 16 – – – 16 – – –
Ciprofloxacin
All 0.008 100 – – 0.015 100 – – 0.008 100 – – 0.015 100 – –
b-Lactamase-
negative
0.008 100 – – 0.015 100 – – 0.008 100 – – 0.015 100 – –
b-Lactamase-
positive
0.015 100 – – 0.008 100 – – 0.015 100 – – 0.015 100 – –
Levofloxacin
All 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
b-Lactamase-
negative
0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
b-Lactamase-
positive
0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
a137 b-lactamase-negative and 73 b-lactamase-positive isolates collected.
b193 b-lactamase-negative and 17 b-lactamase-positive isolates collected.
c192 b-lactamase-negative and 18 b-lactamase-positive isolates collected.
d160 b-lactamase-negative and 50 b-lactamase-positive isolates collected.
eS¼ susceptible; I¼ intermediate; R¼ resistant.
fNCCLS breakpoints unavailable for categorical interpretation as susceptible, intermediate, or resistant.
gOne isolate was azithromycin non-susceptible (MIC  8 mg/L).
hTwo isolates were azithromycin non-susceptible (MICs  8 mg/L).
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patients18 years old, and 59 (7.0%) from patients
of unknown age. Isolates were submitted to our
central laboratory (Focus Technologies, Herndon,
VA, USA) and subcultured on chocolate agar. The
identity of each isolate was confirmed by using
standard laboratory methods [7], and each isolate
was tested for the production of b-lactamase by
use of the chromogenic substrate nitrocefin (BBL
Dry Slide Nitrocefin, Becton Dickinson, Sparks,
MD, USA).
Antimicrobial susceptibility to ampicillin,
amoxicillin–clavulanate, cefaclor, cefuroxime, azi-
thromycin, clarithromycin, roxithromycin, cipro-
floxacin and levofloxacin was tested by broth
microdilution according to the National Commit-
tee for Clinical Laboratory Standards (NCCLS)
guidelines with the use of frozen microdilution
panels (TREK Diagnostics, Westlake, OH, USA).
Minimum inhibitory concentrations (MICs) for H.
influenzae were interpreted using the NCCLS
M100-S11 recommendations, where available [8].
The NCCLS-recommended quality control strains
H. influenzae ATCC 49247 and H. influenzae ATCC
49766 were used throughout testing.
R E S U L T S
Of the 840 H. influenzae isolates collected, 18.8%
(158/840) were b-lactamase positive and ampicil-
lin resistant (France, 34.8%; Germany, 8.1%; Italy,
8.6%; Spain 23.8%) (Table 1). All of the isolates
tested were susceptible to amoxicillin–clavulanate,
ciprofloxacin and levofloxacin. Cefuroxime sus-
ceptibility was >96% in each country (Table 1).
Overall, H. influenzae isolates collected from
patients 4 years old had the highest prevalence
of b-lactamase production (23.2%). b-Lactamase
production was >5% lower among isolates col-
lected from patients aged 5–17 years (17.8%) and
18 years (16.5%) than among patients 4 years
old; this pattern was observed in all countries.
Macrolide activity was unaffected by b-lacta-
mase production, as MIC distributions were simi-
lar for both b-lactamase-negative and b-lactamase-
positive isolates (Figure 1). In all countries, azi-
thromycin (MIC90, 2 mg/L;99% susceptible) was
more potent than clarithromycin (MIC90, 16 mg/L;
<83% susceptible) and roxithromycin (MIC90,
16 mg/L; no interpretive criteria) (Table 1). Three
Figure 1 MIC distributions of macro-
lides against H. influenzae according
to b-lactamase status.
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azithromycin-non-susceptible H. influenzae iso-
lates were collected (France, one isolate; Spain,
two isolates); all were collected from respiratory
specimens of male outpatients ranging in age from
4 to 37 years (data not shown). Azithromycin MICs
for the three isolates were 8, 8 and >64 mg/L
(confirmed by repeat testing), while clarithromy-
cin and roxithromycin MICs were consistently
higher (16, 32 and >128 mg/L for both agents;
data not shown).
D I S C U S S I O N
The prevalence of b-lactamase production
reported here (18.8%) is similar to that previously
reported in other studies of H. influenzae in Europe
[6,9,10]. The 2000 SENTRY study reported a b-
lactamase prevalence of 12.6% [9]. The 1998 Alex-
ander Project, which included France, Germany
and Italy among the 14 countries studied, reported
the prevalence of b-lactamase production to be
11.6% [10]. A 1997–98 European surveillance study
performed by Sahm et al reported b-lactamase
production among H. influenzae isolates collected
from five countries to be 19.4% [10]. On a per
country basis, Sahm et al reported b-lactamase
frequencies similar to those observed here: France,
27.6%; Germany, 5.7%; Italy, 7.7%; and Spain,
32.0% [10]. In the USA, the frequency of b-lacta-
mase production has been reported to be as high as
33% [11], which is similar to the frequencies
observed in France and Spain. While overall fre-
quencies of b-lactamase production in the USA
have reached a plateau [12,13], the frequency
detected here was slightly higher than in previous
years, suggesting that, in some European coun-
tries, b-lactamase production may be increasing.
Historically, azithromycin has been shown to be
more active than erythromycin against Gram-
negative organisms, due to the positive charge
created by a methyl-substituted nitrogen in the
15-membered macrolide ring [14,15]. Based on the
MIC90 in this study, azithromycin (2 mg/L in all
countries) was more potent than both clarithromy-
cin (16 mg/L in all countries) and roxithromycin
(16 mg/L in all countries). Macrolide potency was
unaffected by b-lactamase production. The MIC90s
reported here for azithromycin were identical to
those reported in the 1997–98 European surveil-
lance by Sahm et al [6]; however, the clarithromy-
cin MIC90 of 16 mg/L was one doubling dilution
higher than this study, but identical to that
reported in the 2000 SENTRY study [9]. The
MIC90 of roxithromycin was one dilution lower
(16 mg/L) than reported in previous studies [2,16].
The MIC90s of both azithromycin and clarithromy-
cin were identical to those reported in the USA
during the 1990s [13,17,18], suggesting that the
overall potencies of the macrolides against clinical
isolates of H. influenzae have not changed in recent
years.
Three azithromycin-non-susceptible H. influen-
zae isolates were collected, one of which demon-
strated an azithromycin MIC of >64 mg/L and
clarithromycin and roxithromycin MICs of
>128 mg/L. These unusually high MICs were also
reported in the 1992–97 Alexander Project [19], as
two isolates collected in 1997 were found to have
azithromycin MICs 32 mg/L. Further work is
necessary to determine the mechanism of resis-
tance for these types of isolate.
Overall, >99% of the H. influenzae isolates tested
were susceptible to amoxicillin–clavulanate, cipro-
floxacin, levofloxacin and azithromycin, despite
variations in b-lactamase production among coun-
tries.
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